Ocular Surface Disease Clinical Trial
Official title:
A Phase III, Multinational, Multicenter, Investigator-Masked, Randomized, Active Controlled Trial, Comparing the Efficacy and Safety of DE-130A With Xalatan® in Patients With Open-Angle Glaucoma or Ocular Hypertension Over a 3-Month Period, Followed by a 12-Month Follow-Up With Open-Label DE-130A Treatment.
A Phase III, Multinational, Multicenter, Investigator-Masked, Randomized, Active-Controlled Trial, comparing the efficacy and safety of DE-130A with Xalatan® in Patients with Open-Angle Glaucoma or Ocular Hypertension over a 3-Month period, followed by a 12-Month Follow-Up with Open-Label DE-130A Treatment.
Phase III, prospective, interventional, multinational, multicentre, investigator-masked, randomized, active-controlled trial Study duration: - 5 days to 5-week washout period - 15 months for the first 130 patients - 12 weeks for the next 250 patients Patients will attend 6 visits following the wash-out phase (up to 5 weeks): - Period 1 (3-month investigator-masked treatment period, DE-130A vs Xalatan®): Randomization/Baseline visit (Day 1), Week 4 (±3 days) and Week 12 (±3 days) - Period 2 (12-month follow-up from Week 12, open-label DE-130A treatment for the first 130 patients who complete their week 12 visit and agree to participate in the open-label period of the study): Month 6 (± 7days), Month 9 (±7 days) and Month 15 (± 1 week) visits. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT04067973 -
Impact of Prematurity on the Optic Nerve
|
||
| Completed |
NCT04828057 -
Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting
|
||
| Not yet recruiting |
NCT06375343 -
Study to Evaluating PRO-240 Ophthalmic Solution Compared to Optive®
|
Phase 1 | |
| Completed |
NCT00346450 -
Autologous ex Vivo Conjunctival Epithelial Cell Expansion for Ocular Surface Transplantation
|
Phase 3 | |
| Completed |
NCT04351100 -
Efficacy of Diacerein on Ocular Surface Disease in Degenerative Arthritis Patients
|
||
| Completed |
NCT03659955 -
Autologous Blood Treatment for Ocular Surface Disease
|
N/A | |
| Completed |
NCT04536129 -
Effects of Topical Low Dose Preservative-free Hydrocortisone on Intraocular Pressure
|
N/A | |
| Completed |
NCT01254370 -
Safety and Efficacy Study of Catioprost® (Unpreserved Latanoprost 0.005% Emulsion) Compared to Travatan Z® to Treat Glaucoma and Ocular Surface Disease
|
Phase 2 | |
| Completed |
NCT00554411 -
Assessing Ocular Surface Changes After Changing Glaucoma Medications
|
N/A | |
| Completed |
NCT03769454 -
A Phase I Study of PP-001 Eye Drops in Healthy Adult Volunteers
|
Phase 1 | |
| Recruiting |
NCT06256770 -
Evaluation of the Safety and Efficacy of Rigid Breathable Scleral Contact Lenses for the Correction of Ametropia
|
||
| Completed |
NCT04673604 -
From Preserved, to Preservative-free Cyclosporine 0.1% Enhanced Triple Glaucoma Therapy
|
N/A | |
| Not yet recruiting |
NCT06370585 -
Clinical Study to Evaluate the Safety and Tolerability of PRO-229 Ophthalmic Solution Compared to Lagricel® Ofteno PF
|
Phase 1 | |
| Withdrawn |
NCT04735510 -
Novel Use of Restasis and PROSE Devices
|
Phase 3 | |
| Suspended |
NCT00348114 -
Transplantation of Cultivated Limbal Epithelium on Amniotic Membrane for Limbal Stem Cell Deficiency
|
Phase 2 | |
| Recruiting |
NCT04010422 -
Ocular Function in Autism Spectrum Disorder
|
||
| Completed |
NCT05528016 -
Short and Long-term Results of Skin Versus Skin Plus Orbicularis Resection Blepharoplasty
|
N/A | |
| Completed |
NCT04452279 -
Ocular Surface Disease Changes After iStent or iStent Inject Implantation With Phacoemulsification
|
N/A | |
| Completed |
NCT04535388 -
LK Scleral Lens for Patients With Intractable Ocular Surface Diseases
|
N/A | |
| Recruiting |
NCT06298890 -
The Pattern of Dry Eye Disease After Cataract Surgery
|